Twenty of the 22 therapeutic drugs are approved for NSCLC as the initial indication, and most of them are classified as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors. This evidence concerns the gene ALK and non-small cell lung carcinoma.